ArticleScientific reports2025
Integrated systems biology reveals an 8-gene signature predicting early-stage lung adenocarcinoma progression and patient survival.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identifying Epithelial-Cell Progression Signatures (ECPSs) from Multi-Resolution Multi-Omics Data for Translational Clinical Applications in Lung Adenocarcinoma.International journal of molecular sciences · 2026Article
- CCDC78 is required for prostate cancer cell growth and serves as a prognostic biomarker for high-risk disease.Discover oncology · 2026Article
- Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapy.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A comprehensive analysis of the transcriptomic landscape in early-stage LUAD (stages 1 and 2) can identify robust survival and staging predictors. Using a systems-biology approach with TCGA LUAD transcriptomic data, we identified 18 co-expression modules, 11 correlated with staging and 7 with survival. Five survival- and staging-associated (SAS) modules (M1, M3, M6, M9, and M16) distinguished patients with differing survival curves based on module eigengene expression. Anti-correlated SAS-modules (M3 and M6) exhibited the strongest associations with OS and staging. Key differentially-expressed hub genes from M3 and M6 were nominated as prognostic markers through iterative combinatorial ROC analysis. Survival prediction was refined by testing equal-weight gene ratios with opposing correlations to survival, revealing additive or synergistic predictive value. The top-performing ratio, ATP6V0E1 + SVBP + HSDL1 + UBTD1/GNPNAT1 + XRCC2 + TFAP2A + PPP1R13L, achieved an average AUC of 75.5% across three timepoints (12 months, 18 months, and 3 years). Comparison with three established LUAD prognostic signatures (Shedden, Soltis, and Song) within the TCGA network showed that our 8-gene signature had comparable or superior predictive power while maintaining concordance with existing signatures, some of which contain an order of magnitude more transcripts. Our findings suggest that novel gene signature holds promise for refining early-stage LUAD prognostic modeling and informing treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.